Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TY-9591 tablet plus chemotherapy as first-line treatment for EGFR-mutant advanced or metastatic NSCLC (Phase II)
CTR20244968Phase 2Active
- Sponsor
- TYK Medicines
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of asandeutertinib in non-small cell lung cancer (NSCLC), sponsored by TYK Medicines. Started Mar 2025; status: active.
02
Drugs
asandeutertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20244968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244968.